

Nivolumab CheckMate025

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Improved QoL

Serious and disabling adverse effects



Less serious and disabling adverse events observed


Other adjustments



Nivolumab CheckMate025

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
 Therapeutic Indication: As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults
 Experimental Arm: Nivolumab
 Control Arm: Everolimus



